Table 2 Primary and secondary efficacy and safety outcomes
Study variables | Vancomycin (n = 7) | Daptomycin (n = 7) | All (n = 14) |
|---|---|---|---|
Day-60 mortality | 1 | 0 | 1 |
Microbiological failure | 0 | 0 | 0 |
Recurrence | 1 | 0 | 1 |
Time to microbiological clearance, days (median, IQR) | 4 (3, 5) | 4 (3, 7) | 4 (3, 5) |
Musculoskeletal toxicity | 0 | 1 | 1 |
Nephrotoxicity | 0 | 1 | 1 |
Study drug discontinued due to toxicity | 1 | 1 | 2 |
Study drug discontinued due to worsening infection | 0 | 0 | 0 |
Addition of a second MRSA agent due to worsening infection | 0 | 0 | 0 |